PDF下载 ( 1893 KB)
《原发性肝癌诊疗指南(2022年版)》解读
DOI: 10.3969/j.issn.1001-5256.2022.05.010
利益冲突声明：所有作者均声明不存在利益冲突。
作者贡献声明：李照负责研究数据的获取分析和起草文章；朱继业负责指导写作，并修改文章关键内容。
Interpretation of Standard for diagnosis and treatment of primary liver cancer (2022 edition)
-
-
Key words:
- Liver Neoplasms /
- Diagnosis /
- Therapeutics /
- Practice Guidelines as Topic
-
[1] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. [2] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. [3] FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025. [4] ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697. [5] XIA Y, LI J, LIU G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial[J]. JAMA Oncol, 2020, 6(2): 255-263. DOI: 10.1001/jamaoncol.2019.4477. [6] HIDAKA M, EGUCHI S, OKUDA K, et al. Impact of anatomical resection for hepatocellular carcinoma with microportal invasion (vp1): A multi-institutional study by the Kyushu Study Group of Liver Surgery[J]. Ann Surg, 2020, 271(2): 339-346. DOI: 10.1097/SLA.0000000000002981. [7] LI PP, HUANG G, JIA NY, et al. Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study[J]. Hepatobiliary Surg Nutr, 2022, 11(1): 38-51. DOI: 10.21037/hbsn-20-264. [8] MAZZAFERRO V, CITTERIO D, BHOORI S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21(7): 947-956. DOI: 10.1016/S1470-2045(20)30224-2. [9] KASEB AO, TRAN CAO HS, MOHAMED YI, et al. Final results of a randomized, open label, perioperative phase Ⅱ study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol, 2020, 38(15_suppl): 4599. [10] SUN HC, ZHU XD, ZHOU J, et al. Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase Ⅱ study[J]. J Clin Oncol, 2020, 38(4_suppl): 514. [11] ZHU XD, HUANG C, SHEN YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313. [12] WANG Z, REN Z, CHEN Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: A randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081. DOI: 10.1158/1078-0432.CCR-17-2899. [13] LIANG B, MAKAMURE J, SHU S, et al. Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma: A meta-analysis[J]. Front Oncol, 2021, 11: 576232. DOI: 10.3389/fonc.2021.576232. -
本文二维码
计量
- 文章访问数: 1535
- HTML全文浏览量: 253
- PDF下载量: 547
- 被引次数: 0
下载:
